These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 17166337)
21. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805 [TBL] [Abstract][Full Text] [Related]
22. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
23. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826 [TBL] [Abstract][Full Text] [Related]
25. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198 [TBL] [Abstract][Full Text] [Related]
26. Development and application of Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS): an Australian economic model for stroke. Mihalopoulos C; Cadilhac DA; Moodie ML; Dewey HM; Thrift AG; Donnan GA; Carter RC Int J Technol Assess Health Care; 2005; 21(4):499-505. PubMed ID: 16262974 [TBL] [Abstract][Full Text] [Related]
27. Functional form and risk adjustment of hospital costs: Bayesian analysis of a Box-Cox random coefficients model. Hollenbeak CS Stat Med; 2005 Oct; 24(19):3005-18. PubMed ID: 15977298 [TBL] [Abstract][Full Text] [Related]
28. The quality of three decision-analytic diabetes models: a systematic health economic assessment. Becker C; Langer A; Leidl R Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):751-62. PubMed ID: 22098291 [TBL] [Abstract][Full Text] [Related]
29. Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe. Hermansson J; Kahan T Pharmacoeconomics; 2018 Feb; 36(2):205-213. PubMed ID: 29079929 [TBL] [Abstract][Full Text] [Related]
30. An alternative approach identified optimal risk thresholds for treatment indication: an illustration in coronary heart disease. van Giessen A; de Wit GA; Moons KGM; Dorresteijn JAN; Koffijberg H J Clin Epidemiol; 2018 Feb; 94():122-131. PubMed ID: 28986242 [TBL] [Abstract][Full Text] [Related]
32. Validation by simulation of a clinical trial model using the standardized mean and variance criteria. Abbas I; Rovira J; Casanovas J J Biomed Inform; 2006 Dec; 39(6):687-96. PubMed ID: 16464642 [TBL] [Abstract][Full Text] [Related]
33. Do Statins Reduce the Health and Health Care Costs of Obesity? Gaudette É; Goldman DP; Messali A; Sood N Pharmacoeconomics; 2015 Jul; 33(7):723-34. PubMed ID: 25576147 [TBL] [Abstract][Full Text] [Related]
34. The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. Ye W; Brandle M; Brown MB; Herman WH Diabetes Technol Ther; 2015 Oct; 17(10):701-11. PubMed ID: 26222704 [TBL] [Abstract][Full Text] [Related]
35. Event simulation and external validation applied in published health economic models for obesity: a systematic review. Schwander B; Nuijten M; Hiligsmann M; Evers SMAA Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):529-541. PubMed ID: 30011385 [TBL] [Abstract][Full Text] [Related]
36. The development of a simulation model of primary prevention strategies for coronary heart disease. Babad H; Sanderson C; Naidoo B; White I; Wang D Health Care Manag Sci; 2002 Nov; 5(4):269-74. PubMed ID: 12437274 [TBL] [Abstract][Full Text] [Related]
37. Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. Albuquerque de Almeida F; Corro Ramos I; Rutten-van Mölken M; Al M Value Health; 2021 Oct; 24(10):1435-1445. PubMed ID: 34593166 [TBL] [Abstract][Full Text] [Related]